May 29, 2018
CASI Pharmaceuticals To Present At The BIO International ConventionMay 15, 2018
CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business ResultsApril 05, 2018
CASI Pharmaceuticals Provides Update On Evomela®April 03, 2018
CASI Pharmaceuticals To Present At The H.C. Wainwright Global Life Sciences ConferenceMarch 29, 2018
CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial ResultsMarch 20, 2018
CASI Pharmaceuticals Announces $50 Million Private Placement To Prepare Company For Commercialization In ChinaFebruary 09, 2018
CASI Pharmaceuticals to Present at the BIO CEO & Investor ConferenceJanuary 26, 2018
CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)December 01, 2017
CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)November 14, 2017
CASI Pharmaceuticals Reports Third Quarter 2017 Financial ResultsOctober 13, 2017
CASI PHARMACEUTICALS ANNOUNCES $23.8 MILLION REGISTERED DIRECT OFFERING LED BY EXISTING SHAREHOLDERSSeptember 07, 2017
CASI Provides Pipeline Development UpdateSeptember 06, 2017
CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment ConferenceAugust 14, 2017
CASI Pharmaceuticals Reports Second Quarter 2017 Financial ResultsMay 30, 2017
CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma (CCOC)May 18, 2017
CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian CancerMay 15, 2017
CASI Pharmaceuticals Reports First Quarter 2017 Financial ResultsApril 14, 2017
CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast CancerMarch 31, 2017
CASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial ResultsMarch 28, 2017
CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting
